Eur Heart J: LDL-C in patients with myocardial infarction reduces the intensity and major adverse outcomes of statin medication

Clinical trials have shown that reducing LDL-C can reduce cardiovascular (CV) events.
, researchers looked at the relationship between LDL-C changes after myocardial infarction (MI) and the prognostics of statin strength, according to a recent study published in Eur Heart J, an authoritative journal in the field of cardiovascular medicine.
patients admitted to the hospital followed up on their mortality rates and major cardiovascular events.
researchers analyzed changes in LDL-C between MI and follow-up for 6 to 10 weeks, and used adjusted Cox regression analysis to assess the correlation between the quatecles of LDL-C changes and the intensity of statins and patient outcomes.
the study followed a total of 40,607 patients, with a medium time of 3.78 years.
change in LDL-C is reduced by 1.20 mmol/L.
LDL-C decreased significantly (1.85 mmol / L, 75th percentile) compared to patients with a smaller LDL-C reduction (0.36 mmol/L, 25 percentiles) All outcome risk ratios (HR) were lower: a compound outcome of 0.77 (0.70-0.84) for mortality, MI and ischemic stroke; 80); cardiovascular mortality is 0.68 (0.57-0.81); MI is 0.81 (0.73-0.91); ischemic stroke is 0.76 (0.91) 62-0.93); Hospitalization for heart failure was 0.73 (0.63-0.85) and coronary artery blood transport reconstruction was 0.86 (0.79-0.94).
patients who were discharged with low-intensity statins also had a lower risk of all outcomes in patients who were discharged with high-intensity statins, who were treated with high-intensity statins, who were 50 percent less likely to have an LDL-C≥
, it can be seen that the higher and higher intensity statins in the early post-MI LDL-C are associated with a reduced risk of all CV outcomes and all-cause mortality.
these results support clinical trial data, suggesting that reducing LDL-C early after MI has the greatest benefit.
。